Ipsen SA (IPN: FP) (OTC: IPSEF), a worldwide biopharmaceutical firm, has obtained an upgraded inventory score from RBC Capital. The agency raised its score from Sector Carry out to Outperform, with the worth goal additionally growing to EUR 140.00 from the earlier EUR 129.00.
The improve got here after RBC Capital reviewed Ipsen’s monetary outlook following the U.S. approval of the corporate’s drug Iqirvo for Main Biliary Cholangitis (PBC).
The analyst from RBC Capital famous that they now anticipate the height gross sales for Iqirvo to achieve EUR 540 million, a major leap from the preliminary EUR 300 million estimate. This upward revision is anticipated to spice up Ipsen’s earnings per share (EPS) forecasts by as much as 9%.
The analyst’s analysis means that Ipsen’s shares are at present undervalued, with a price-to-earnings (PE) ratio of 11.3x. This valuation is seen as engaging given the corporate’s potential for a 9% compound EPS progress over the medium time period.
The revised discounted money movement (DCF) evaluation has led to the upper worth goal, which suggests a possible upside of over 30% for Ipsen’s inventory.
This text was generated with the assist of AI and reviewed by an editor. For extra info see our T&C.
